While PR-positive tumors are the most apparent candidates, further investigation is warranted to determine the benefit of this approach in broader subgroups, including patients with obesity-driven disease or mismatch repair–deficient (MMR-d) tumors, which may exhibit partial hormonal responsiveness. This evidence concerns the gene PGR and obesity disorder.